Journal
GENES
Volume 13, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/genes13010074
Keywords
McArdle disease; glycogen; glycogen phosphorylase; research models; treatments
Categories
Funding
- Fondo de Investigaciones Sanitarias (FIS) [PI19/01313, PI17/2052]
- Fondos FEDER
Ask authors/readers for more resources
In this study, the existing in vitro and in vivo preclinical models for McArdle disease are described, and the insights provided by these models are reviewed. Despite some differences from the typical patient phenotype, these models allow for a thorough study of the different features of the disease and serve as a necessary preclinical step to evaluate treatment efficacy and safety.
McArdle disease is an autosomal recessive disorder of muscle glycogen metabolism caused by pathogenic mutations in the PYGM gene, which encodes the skeletal muscle-specific isoform of glycogen phosphorylase. Clinical symptoms are mainly characterized by transient acute crises of early fatigue, myalgia and contractures, which can be accompanied by rhabdomyolysis. Owing to the difficulty of performing mechanistic studies in patients that often rely on invasive techniques, preclinical models have been used for decades, thereby contributing to gain insight into the pathophysiology and pathobiology of human diseases. In the present work, we describe the existing in vitro and in vivo preclinical models for McArdle disease and review the insights these models have provided. In addition, despite presenting some differences with the typical patient's phenotype, these models allow for a deep study of the different features of the disease while representing a necessary preclinical step to assess the efficacy and safety of possible treatments before they are tested in patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available